Despite a recent corruption scandal, Sun Pharma’s stock performance has been strong. The company has been able to weather the storm and emerge stronger than ever.
What is Sun Pharma’s share price today
Sun Pharma is one of the leading pharmaceutical companies in India with a share price of Rs. 984.80 as of today. The company has a market capitalization of Rs. 1,21,517.54 crore and a 52-week high/low of Rs. 993.95/Rs. 564.60. Sun Pharma’s share price has been on an uptrend in the last few months on the back of strong financial performance and positive investor sentiment. The company posted a healthy growth in sales and profits in the last quarter, driven by strong demand for its products in both domestic and international markets. The stock is trading at a P/E ratio of 34.72 and has a dividend yield of 0.86%.
How has Sun Pharma’s share price performed over the past year
Sun Pharma’s share price has performed well over the past year. The company’s stock price has increased by nearly 20% during that time, outperforming the broader market. Sun Pharma is a leading Indian pharmaceutical company with a strong presence in both the domestic and international markets. The company’s products are well-regarded and its financials are solid. Additionally, Sun Pharma has been proactive in pursuing mergers and acquisitions, which has helped to boost its growth. Overall, Sun Pharma is a strong company with a bright future, and its share price is reflective of that.
What factors have influenced Sun Pharma’s share price in the past
Sun Pharma is India’s largest pharmaceutical company with a market capitalization of over US$40 billion. The company’s share price has been on a roller coaster ride in the past, with a number of factors influencing its ups and downs.
One of the biggest drivers of Sun Pharma’s share price has been the performance of the Indian stock market. When the market is doing well, Sun Pharma’s shares tend to outperform, while when the market is struggling, the stock usually lags behind. This is because investors see Sun Pharma as a bellwether for the Indian economy, and its share price is seen as a barometer for how well the country is doing.
Another important factor that has influenced Sun Pharma’s share price is the company’s own financial performance. When Sun Pharma has reported strong quarterly results, its shares have usually risen, while weak results have typically led to a sell-off. This is because investors believe that Sun Pharma is a well-run company with a bright future, and they are willing to pay a premium for its shares when the company is doing well.
Finally, political and regulatory developments in India can also impact Sun Pharma’s share price. For example, if there is positive news about India’s economic reform program or progress on combating corruption, Sun Pharma’s shares usually rise. On the other hand, if there are negative headlines about these issues, the stock usually takes a hit.
What is Sun Pharma’s market capitalization
Sun Pharma’s market capitalization is $42.5 billion.
What is the history of Sun Pharma
Sun Pharma is an Indian multinational pharmaceutical company headquartered in Mumbai, Maharashtra. It is the fifth largest specialty generic pharmaceutical company in the world. Sun Pharma was founded in 1983 by Dilip Shanghvi. The company’s core business is the development and manufacture of pharmaceutical products. Sun Pharma has over 30,000 employees and operates in over 150 countries.
The company’s focus on innovation has led to it being one of the world’s leading producers of generic drugs. In addition to its generic drug business, Sun Pharma also has a strong presence in the branded drugs market. The company’s flagship brands include Revital (vitamins and supplements), Ranbaxy (pharmaceuticals), and Sunburn (suncare products).
Sun Pharma has a long history of commitment to research and development (R&D). The company has over 1,500 scientists working in R&D across its global sites. In FY2019, Sun Pharma’s R&D expenditure was INR 10.4 billion (US$ 150 million), representing approximately 6% of its total revenue.
Sun Pharma’s success is built on a strong foundation of ethical business practices. The company is committed to complying with all applicable laws and regulations. It has a comprehensive code of conduct that sets out the standards expected of its employees, suppliers, and other business partners.
Who are the major shareholders of Sun Pharma
Sun Pharma is an Indian multinational pharmaceutical company headquartered in Mumbai, Maharashtra. It is the largest pharmaceutical company in India with a market capitalization of ₹1,28,757 crore (US$17.9 billion) as of March 2020. The company was founded by Dilip Shanghvi in 1982 and today it has over 30,000 employees in over 150 countries.
The company’s share price has been on a roller coaster ride in recent years. In 2015, Sun Pharma shares hit a 52-week high of ₹1,206 but fell to a low of ₹484 in 2016. In 2017, the shares recovered to ₹844 but fell again to ₹457 in 2018. However, the shares have been on the rise since then and hit a 52-week high of ₹968 in 2019.
So who are the major shareholders of Sun Pharma?
According to the latest data available, the top 10 shareholders of Sun Pharma are:
1. Vanguard Group Inc – 5.62%
2. BlackRock Inc – 4.74%
3. State Street Corporation – 2.71%
4. Fidelity Management & Research Company LLC – 1.96%
5. Norges Bank Investment Management – 1.63%
6. BNP Paribas Asset Management France – 1.47%
7. Dimensional Fund Advisors LP – 1.35%
8. T Rowe Price Associates Inc – 1.11%
9. Lazard Asset Management LLC – 0.95%
10. JPMorgan Chase & Co – 0.93%
What are Sun Pharma’s main products and services
Sun Pharma is a leading pharmaceutical company with a presence in over 100 countries. The company offers a wide range of products and services, including prescription and over-the-counter drugs, vaccines, and medical devices. Sun Pharma’s primary focus is on innovation and providing affordable access to quality medicines for all.
What are Sun Pharma’s competitors
Sun Pharma is a global pharmaceutical company with a presence in over 100 countries. The company’s products are marketed in over 60 countries. Sun Pharma has a strong research and development focus, and has over 8,500 employees worldwide.
The company’s main competitors are Dr. Reddy’s Laboratories, Glenmark Pharmaceuticals, Lupin, Cadila Healthcare, and Aurobindo Pharma. These companies are all based in India and are among the leading pharmaceutical companies in the world.
Where is Sun Pharma headquartered
Sun Pharma is an Indian multinational pharmaceutical company that is headquartered in Mumbai, Maharashtra. It is the fifth largest specialty generic pharmaceutical company in the world and the largest pharmaceutical company in India with a market capitalization of over $40 billion.